Literature DB >> 29206889

Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.

A Guihot1, A-G Marcelin2, M-A Massiani3, A Samri4, C Soulié5, B Autran6, J-P Spano7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29206889     DOI： 10.1093/annonc/mdx696

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  67 in total

1.  Functional immune characterization of HIV-associated non-small-cell lung cancer.

Authors:  D J Pinato; A Kythreotou; F A Mauri; E Suardi; E Allara; R J Shiner; A U Akarca; P Trivedi; N Gupta; A Dalla Pria; T Marafioti; P Oliveri; T Newsom-Davis; M Bower
Journal:  Ann Oncol       Date:  2018-06-01       Impact factor: 32.976

2.  Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design.

Authors:  Ruian Ke; Jessica M Conway; David M Margolis; Alan S Perelson
Journal:  JCI Insight       Date:  2018-10-18

3.  Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection.

Authors:  E P Scully; R L Rutishauser; C R Simoneau; H Delagrèverie; Z Euler; C Thanh; J Z Li; H Hartig; S Bakkour; M Busch; G Alter; F M Marty; C-C Wang; S G Deeks; J Lorch; T J Henrich
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

Review 4.  Immunologic Control of HIV-1: What Have We Learned and Can We Induce It?

Authors:  Daniel C Rogan; Mark Connors
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-11       Impact factor: 5.071

Review 5.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

Review 6.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

Review 7.  Between a shock and a hard place: challenges and developments in HIV latency reversal.

Authors:  Jennifer M Zerbato; Harrison V Purves; Sharon R Lewin; Thomas A Rasmussen
Journal:  Curr Opin Virol       Date:  2019-04-29       Impact factor: 7.090

8.  Low frequency, weak MCP-1 secretion and exhausted immune status of peripheral monocytes were associated with progression of severe enterovirus A71-infected hand, foot and mouth disease.

Authors:  X Pei; X Fan; H Zhang; H Duan; C Xu; B Xie; L Wang; X Li; Y Peng; T Shen
Journal:  Clin Exp Immunol       Date:  2019-02-17       Impact factor: 4.330

9.  CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption.

Authors:  Justin Harper; Shari Gordon; Chi Ngai Chan; Hong Wang; Emily Lindemuth; Cristin Galardi; Shane D Falcinelli; Samuel L M Raines; Jenna L Read; Kevin Nguyen; Colleen S McGary; Michael Nekorchuk; Kathleen Busman-Sahay; James Schawalder; Colin King; Maria Pino; Luca Micci; Barbara Cervasi; Sherrie Jean; Andrew Sanderson; Brian Johns; A Alicia Koblansky; Heather Amrine-Madsen; Jeffrey Lifson; David M Margolis; Guido Silvestri; Katharine J Bar; David Favre; Jacob D Estes; Mirko Paiardini
Journal:  Nat Med       Date:  2020-03-16       Impact factor: 53.440

Review 10.  Cancer immunotherapy of patients with HIV infection.

Authors:  M Gonzalez-Cao; J Martinez-Picado; N Karachaliou; R Rosell; A Meyerhans
Journal:  Clin Transl Oncol       Date:  2018-11-17       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.